Patients with multiple myeloma (MM) typically relapse or become refractory (RR) to multiple lines/classes of treatment over the course of their disease. Patients treated with the three major classes of therapies (proteasome inhibitors [PI], immunomodulatory drugs [IMiD], anti-CD38 monoclonal antibodies) are considered triple-class exposed (TCE) have limited treatment options and poor prognosis once they become RRMM. This study describes the real-world characteristics and treatment patterns of Medicare beneficiaries with TCE RRMM.